EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Toni K Choueiri, Thomas Powles, Laurence Albiges, Mauricio Burotto, Cezary Szczylik, Bogdan Zurawski, Eduardo Yanez Ruiz, Marco Maruzzo, Alberto Suarez Zaizar iD, Luis E Fein, Fabio A Schutz, Daniel Y C Heng und 7 weitere

New England Journal of Medicine · 11.05.2023 · 388 (19) · 1767-1778

DOI: 10.1056/nejmoa2212851 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 11.05.2023. Verfasst von Toni K Choueiri und 18 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harv…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Exelixis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsHumansIpilimumabNivolumabPrognosisDouble-Blind MethodSurvival AnalysisAnilidesPyridines

Substanzen

IpilimumabNivolumabcabozantinibAnilidesPyridines

Autor:innen und Institutionen

  • From the Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School - both in Boston (T.K.C.); the Department of Genito…

ORCID-Profile: Alberto Suarez Zaizar

Förderung

  • NCI NIH HHS
  • Exelixis

Zitieren

APA

Choueiri, T. K., Powles, T., Albiges, L., Burotto, M., Szczylik, C., Zurawski, B., Yanez Ruiz, E., Maruzzo, M., Suarez Zaizar, A., Fein, L. E., Schutz, F. A., Heng, D. Y. C., Wang, F., Mataveli, F., Chang, Y. L., van Kooten Losio, M., Suarez, C., Motzer, R. J., & COSMIC-313 Investigators (2023). Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. New England Journal of Medicine, 388(19), 1767-1778. https://doi.org/10.1056/nejmoa2212851

Vancouver

Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. New England Journal of Medicine. 2023;388(19):1767-1778. doi:10.1056/nejmoa2212851

BibTeX
@article{Choueiri2023,
  author = {Choueiri, Toni K and Powles, Thomas and Albiges, Laurence and Burotto, Mauricio and Szczylik, Cezary and Zurawski, Bogdan and Yanez Ruiz, Eduardo and Maruzzo, Marco and Suarez Zaizar, Alberto and Fein, Luis E and Schutz, Fabio A and Heng, Daniel Y C and Wang, Fong and Mataveli, Fabio and Chang, Yu-Lin and van Kooten Losio, Maximiliano and Suarez, Cristina and Motzer, Robert J and COSMIC-313 Investigators, COSMIC-313 Investigators},
  title = {Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {19},
  pages = {1767--1778},
  doi = {10.1056/nejmoa2212851}
}
Kostenlos starten →